Annual report pursuant to Section 13 and 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

v3.22.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS
 12 Months Ended
Dec. 31, 2021
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

NOTE 15. REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS

Disaggregation of Net Revenues

The Company has the following actively marketed products, Qbrexza®, Accutane®, Targadox®, Ximino®, Exelderm®, and Luxamend®. All of the Company’s product revenues are recorded in the U.S.

​

Revenues by product are summarized as follows:

​

​

​

​

​

​

​

​

​

    

December 31, 

($’s in thousands)

    

2021

    

2020

Targadox®

​

$

22,378

​

$

30,708

Ximino®

​

 

8,247

​

 

9,518

Exelderm®

​

 

5,363

​

 

4,453

Accutane®

​

 

10,053

​

 

—

Qbrexza®

​

 

17,056

​

 

—

Other branded revenue

​

 

37

​

 

(148)

Total product revenue, net

​

$

63,134

​

$

44,531

​

Significant Customers

As of December 31, 2021, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 16.3% and 12.9%. As of December 31, 2020, one of the Company’s customers accounted for 12% of its total accounts receivable balance.

​

For the year ended December 31, 2021 and 2020, none of the Company’s customers accounted for more than 10% of its total gross product revenue.